This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.

We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.

Events OverviewITM Symposium on Actinium-225 Targeted Radionuclide Therapy at Theranostics World CongressITM Precision Oncology Symposium 2022ITM's Symposium at NuklearMedizin 20222nd ICPO Forum for Theranostics in Precision OncologyITM's ESMO 2021 Industry Satellite SymposiumITM Precision Oncology Symposium 2021COMPETE e-poster at AACR 2021

ITM Precision Oncology Symposium 2022

Targeted Radionuclide Therapy – Present and Future Prospects


Thank you for your interest in ITM’s Precision Oncology Symposium 2022 in parallel to the 2022 ASCO® Annual Meeting.

A recording of the symposium and the ensuing discussion is available to Healthcare Professionals here: View full recording



On behalf of ITM, I would like to invite you to our ancillary event in parallel to the 2022 ASCO® Annual Meeting: “Targeted Radionuclide Therapy – present and future prospects” on Friday June 3, 2022 from 11:00am - 12:30 pm local time in-person and online at the Hyatt Regency McCormick Place, Chicago, IL.  

This symposium will be chaired by Pamela Kunz, MD, Professor and Director of GI Medical Oncology, at Yale Cancer Center, New Haven, Connecticut. Speakers also include the esteemed experts in Radioligand Therapy, Mike Morris, MD, Prostate Cancer Section Head, Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, New York, NY, Wolfgang A. Weber, MD, Professor and Chair, Director of the Department of Nuclear Medicine at “Klinikum rechts der Isar” (the University Hospital of the Technical University Munich), Munich, Germany, and Thomas Hope, MD, Associate Professor Radiology and Director of Molecular Therapy in the Department of Radiology and Biomedical Imaging University of California, San Francisco, CA.

As Targeted Radionuclide Therapy is emerging as a potential approach to treat cancer, new areas of interest and advancing approaches to implementing this selective therapeutic modality continue to evolve.  The session will offer an overview of key topics. The panel will focus on the clinical application of Targeted Radionuclide Therapy in the potential treatment of neuroendocrine tumors, prostate cancer and prospects. They will also spotlight the potential benefits of this therapeutic approach, address challenges that may be encountered and provide valuable insights to their patient management experiences.  

We look forward to your participation. Registration is open at the link below where additional information can be found.  

Val Nassiri,

VP, Head of Medical Affairs US, ITM



Chair: Pamela Kunz, MD


Welcome & Introduction

Clinical Application of Targeted Radionuclide Therapy in Neuroendocrine Tumors
Pamela Kunz, MD, Director, Center for GI Cancers at Smilow Cancer Hospital and Yale Cancer Center

Clinical Application of Targeted Radionuclide Therapy in Prostate Cancer
Michael Morris, MD, Prostate Cancer Section Head, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center

Personalizing the Targeted Radionuclide Therapy, Advancements and Challenges
Thomas Hope, MD, Director of Molecular Therapy in the Department of Radiology and Biomedical Imaging, University of California San Francisco

The future of Targeted Radionuclide Therapy
Wolfgang Weber, MD, PhD, Director of the Department of Nuclear Medicine, "Klinikum rechts der Isar" (the University Hospital of the Technical University of Munich)

Discussion & Closing Remarks



Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO® , CancerLinQ®, or Conquer Cancer® the ASCO Foundation. [if applicable: Not CME  accredited.]